Researchers have determined that CGRP exhibits pain effects in a sex-specific manner. Understanding these sex-specific differences could help us understand why migraines are three-times more common in women than in men.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
Novartis has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults.
Aimovig® (erenumab) has received a positive opinion from the CHMP for migraine, steering the way towards a marketing authorization from the EMA.
Novartis and Amgen have announced that Aimovig® has been approved by the US FDA for the preventive treatment of migraine in adults.
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.
A preliminary study has revealed that a monoclonal antibody could prevent difficult-to-treat migraines in patients who have tried unsuccessfully to prevent them using other treatments.
Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
The latest study assessing the drug erenumab has demonstrated promising results for migraine sufferers who failed to respond to prior treatments.